Hasil Pencarian (14494)
Halaman 66 / 290BF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.
BF-37 for the treatment of atopic dermatitis and/or psoriasis. The active ingredient in BF-37 is Riluzole, applied in a topical formulation, which is believed to correct the imbalances of the immune system that cause atopic dermatitis or psoriasis.
BFH772 is under investigation in clinical trial NCT01449591 (Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients).
Bfpet F-18 is under investigation in clinical trial NCT03265431 (Evaluation of PET/MR in Patients Selected for Ablation Therapy).
BG-777 is an immunomodulator with proven efficacy against viral and bacterial infections in preclinical studies.
BG1805 is an investigational anti-CLL1 chimeric antigen receptor (CAR) T-cell therapy.
BGB-DXP593 is a SARS-CoV-2 neutralizing antibody.[L27401] It is currently being investigated against COVID-19 in the clinical trial NCT04551898 (Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With…
BGT-DTDS is an investigational gene therapy comprising an adeno-associated viral vector type 2 (AAV2) encoding the human _SLC6A3_ gene. It is under investigation for the treatment of dopamine transporter deficiency syndrome (DTDS).
BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.[L48086]
BHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is [lanicemine].[L46446]
BI 2536 is under investigation in clinical trial NCT00376623 (Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer).
BI 44370 TA is under investigation in clinical trial NCT00751803 (BI 44370 TA in Acute Migraine Attack).
BI-1206 is a fully human immunoglobulin G1 monoclonal antibody that targets CD32b.
Bi 671800 has been used in trials studying the treatment of Asthma and Rhinitis, Allergic, Perennial.
BI-765063 is a humanized IgG4 monoclonal antibody antagonist of signal regulatory protein ? (SIRP?).
Deskripsi belum tersedia.
Deskripsi belum tersedia.
BI-K0376 is investigated for use/treatment in acne. BI-K0376 is a solid. It is under investigation by Pfizer and has gone through phase I of the clinical trails.
Biapenem has been used in trials studying the treatment of Bacterial Infections.
Deskripsi belum tersedia.
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Bicifadine (DOV-220075) is a nonopioid analgesic. It is an inhibitor of both the norepinephrine and serotonin transporters and an NMDA antagonist with a non-narcotic profile. Bicifadine was shown to have potent analgesic activity in vivo and was chosen for fu…
Deskripsi belum tersedia.
Bicisate, also known as ethyl cysteinate dimer (ECD), is a N,N'-1,2-ethylene-di-yl-bis-L-cysteinate diethyl ester. It is used in conjunction with technetium Tc99m as a tracer to measure cerebral blood flow with single-photon emission computed tomography (SPEC…
Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.[L43677]
Bicuculline is a light-sensitive competitive antagonist of GABAA receptors. It was originally identified in 1932 in plant alkaloid extracts and has been isolated from Dicentra cucullaria, Adlumia fungosa, Fumariaceae, and several Corydalis species.
Bicyclol is under investigation in clinical trial NCT02944552 (The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI).
Bifenthrin is under investigation in clinical trial NCT01560247 (Percutaneous Recanalization in Ischemic Stroke Management in Europe Observational Registry).
Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, [aripiprazole] and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.
Bifikafusp alfa is under investigation in clinical trial NCT05329792 (L19IL2/L19TNF in Skin Cancer Patients).
Bifunctional epoxide hydrolase 2 is under investigation in clinical trial NCT00654966 (Evaluation of the Effects of Urotensin-II and Soluble Epoxide Hydrolase Inhibitors on Skin Microvessel Tone in Patients With Heart Failure, and in Healthy Volunteers).
BIIB015 is a humanized, IgG1 [immunoglobulin G 1], DM4-Conjugated, anti-cripto, monoclonal antibody. It has been investigated for the treatment of subjects with relapsed or refractory solid tumours.
BIIB115 is an investigational antisense oligonucleotide in development for spinal muscular atrophy.
Bilastine is a novel new-generation antihistamine that is highly selective for the H1 histamine receptor, has a rapid onset and prolonged duration of action.